Ozempic

News

Novo Nordisk sales surge drives value towards $500bn

Fuelled by its diabetes and obesity drugs, Novo Nordisk has reported revenues up a third in 2023, sparking a rise in an already inflated share price that briefly pushed th

News

Novo Nordisk will invest €2.1bn in French manufacturing site

Novo Nordisk has made another major capital investment in production capacity for its diabetes and obesity therapies, agreeing to spend €2.1 billion ($2.3 billion) on a fa

News

Novo Nordisk sets aside $6bn to boost production capacity

Novo Nordisk is leaving nothing to chance when it comes to claiming a stake in the burgeoning market for diabetes and obesity therapies, announcing a plan to spend a whopp

News

Novo Nordisk shrugs off supply issues with record sales

Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt

News

EMA finds no evidence GLP-1 agonists cause thyroid cancer

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’

News

Novo Nordisk’s semaglutide aces another outcomes trial

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft

Novo Nordisk sales surge drives value towards $500bn

Novo Nordisk will invest €2.1bn in French manufacturing site

Novo Nordisk sets aside $6bn to boost production capacity

Novo Nordisk shrugs off supply issues with record sales

EMA finds no evidence GLP-1 agonists cause thyroid cancer

Novo Nordisk’s semaglutide aces another outcomes trial

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Ozempic

Editor's Picks